Bortezomib 2 mg Injection bulk supplier for pharma manufacturers

Bortezomib 2 Mg Injection 1 mg/vial, 3.5 mg/vial, 2 mg Suppliers & Bulk Manufacturers

Available Forms: Injection (lyophilized powder for solution)

Available Strengths: 1 mg/vial, 3.5 mg/vial, 2 mg

Reference Brands: Velcade® (US & EU), Bortecad (India)

Bortezomib Injection is a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma, available in 1 mg and 3.5 mg vials in the US and EU.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Bortezomib Injection, available in 1 mg and 3.5 mg lyophilized vials, is a leading oncology drug used for multiple myeloma and mantle cell lymphoma in the EU and US markets. As a proteasome inhibitor, Bortezomib disrupts protein degradation in cancer cells, inducing apoptosis and inhibiting tumor growth. Marketed under the brand Velcade®, this essential anticancer agent is available for IV and subcutaneous use. GMP-compliant manufacturers supply Bortezomib as a sterile injectable formulation, making it a high-demand product for pharmaceutical B2B sourcing, licensing, and global distribution in regulated markets.

Bortezomib 2 Mg Injection — third party manufacturing & bulk supply

Bortezomib 2 Mg Injection 1 mg/vial, 3.5 mg/vial, 2 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Bortezomib 2 Mg Injection is supplied as Injection (lyophilized powder for solution) — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Bortezomib 2 Mg Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Bortezomib 2 Mg Injection →

Back to Listing

Frequently Asked Questions

Bortezomib is used for the treatment of multiple myeloma and mantle cell lymphoma. It works by inhibiting proteasomes in cancer cells, which leads to the accumulation of proteins inside the cells and ultimately helps slow down or stop the growth of cancer cells.

Bortezomib is a synthetic boronic acid–based compound developed through pharmaceutical research. It belongs to a class of medicines known as proteasome inhibitors that target specific cellular processes involved in cancer cell survival.

Common trade names include Velcade, Bortenat, Bortecad, Borviz, and other regional brands available in global markets.

Bortezomib products are manufactured by companies such as Takeda Pharmaceutical Company and Johnson & Johnson for the original brand Velcade, along with several generic manufacturers in India, Europe, and Latin America.

The generic name is Bortezomib.

Well-known brand names include Velcade (US/EU), Bortenat (India), Bortecad (India), Borviz (India), and several other generic brands available in Europe and Latin American markets.

Bortezomib is manufactured in regulated pharmaceutical facilities in countries such as the United States, India, and several European countries under strict oncology drug manufacturing and quality standards.